Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 11:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Peripheral T-cell Lymphoma (PTCL) Clear all
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Peripheral T-Cell Lymphoma
Interventions
KW-0761
Biological
Lead sponsor
Kyowa Kirin Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
5
States / cities
Los Angeles, California • Stanford, California • New Haven, Connecticut + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced May 21, 2026, 11:25 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Relapsed or Refractory Hodgkin Lymphoma, Peripheral T Cell Lymphoma
Interventions
AFM13, AB-101, Cyclophosphamide, Fludarabine, Interleukin-2
Drug
Lead sponsor
Affimed GmbH
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
15
States / cities
Birmingham, Alabama • Duarte, California • Orange, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced May 21, 2026, 11:25 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Non Hodgkin Lymphoma (NHL), Peripheral T-cell Lymphoma (PTCL), Cutaneous T-Cell Lymphoma (CTCL), Large Granular Lymphocytic Leukemia (LGL-L), T-cell Prolymphocytic Leukemia (T-PLL), Solid Tumors
Interventions
KT-333
Drug
Lead sponsor
Kymera Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
13
States / cities
Orange, California • Louisville, Kentucky • Detroit, Michigan + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced May 21, 2026, 11:25 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Epstein-Barr Virus Associated Lymphoma, EBV-Positive DLBCL, NOS, EBV-Related Non-Hodgkin Lymphoma, EBV Related PTCL, NOS, EBV-Related Hodgkin Lymphoma, EBV-Related PTLD, EBV-Related Lymphoproliferative Disorder
Interventions
Nanatinostat in combination with valganciclovir
Drug
Lead sponsor
Viracta Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
17
States / cities
Birmingham, Alabama • Duarte, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2025 · Synced May 21, 2026, 11:25 PM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Peripheral T-cell Lymphoma (PTCL), PTCL-NOS, ALCL, AITL
Interventions
AZD3470, Pembrolizumab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years and older
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
7
States / cities
Duarte, California • Miami, Florida • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced May 21, 2026, 11:25 PM EDT
Terminated Phase 1 Interventional Results available
View directory record Official record
Conditions
Hematologic Malignancies, Solid Tumor
Interventions
PF-0791800 (TTI-621), PF-07901800 (TTI-621) plus Rituximab, PF-07901800 (TTI-621) plus Nivolumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
47
States / cities
Duarte, California • Palo Alto, California • Denver, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated May 9, 2024 · Synced May 21, 2026, 11:25 PM EDT
Not listed Phase 2 Interventional
View directory record Official record
Conditions
Peripheral T/NK Cell Lymphoma (R/R PTCL)
Interventions
YY-20394
Drug
Lead sponsor
Shanghai YingLi Pharmaceutical Co. Ltd.
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 20, 2022 · Synced May 21, 2026, 11:25 PM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Relapsed or Refractory Peripheral T Cell Lymphoma
Interventions
golidocitinib
Drug
Lead sponsor
Dizal Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
4
States / cities
New Haven, Connecticut • Atlanta, Georgia • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced May 21, 2026, 11:25 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Peripheral T-cell Lymphoma
Interventions
Duvelisib
Drug
Lead sponsor
SecuraBio
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
19
States / cities
Duarte, California • Irvine, California • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced May 21, 2026, 11:25 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Peripheral T-cell Lymphoma
Interventions
20 mg/kg TRU-016 + Rituximab, 10 mg/kg TRU-016 + Rituximab, TRU-016 20 mg/kg + Obinutuzumab, TRU-016 6-20 mg/kg + idelalisib + rituximab, TRU-016 10-20 mg/kg + ibrutinib, TRU-016 10-20 mg/kg + bendamustine
Biological
Lead sponsor
Aptevo Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2021
U.S. locations
8
States / cities
Augusta, Georgia • Columbus, Ohio • Philadelphia, Pennsylvania + 4 more
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced May 21, 2026, 11:25 PM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
Anaplastic Large Cell Lymphoma, Peripheral T Cell Lymphoma, Extranodal NK/T-cell Lymphoma, Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma (PMBCL)
Interventions
CD30.CAR-T
Drug
Lead sponsor
Tessa Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2036
U.S. locations
4
States / cities
Duarte, California • Nashville, Tennessee • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 19, 2023 · Synced May 21, 2026, 11:25 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
T-cell Lymphoma, Cutaneous/Peripheral T-Cell Lymphoma, Peripheral T-cell Lymphoma, Peripheral T-Cell Lymphoma, Not Classified, Primary Cutaneous T-cell Lymphoma, Cutaneous T-Cell Lymphoma, Unspecified, Cutaneous T-cell Lymphoma, Follicular T-Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Sézary's Disease, Mycosis Fungoides
Interventions
Fenretinide
Drug
Lead sponsor
SciTech Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
10
States / cities
Scottsdale, Arizona • Duarte, California • Los Angeles, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced May 21, 2026, 11:25 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
PTCL
Interventions
Azacytidine, Romidepsin, Belinostat, Pralatrexate, Gemcitabine
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
6
States / cities
Long Beach, California • New Haven, Connecticut • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced May 21, 2026, 11:25 PM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Follicular Lymphoma (FL/Indolent NHL), Aggressive NHL (a NHL), Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL), T-cell Lymphoma (PTCL and CTCL), B-cell Non Hodgkin Lymphoma (NHL)
Interventions
Cerdulatinib, Rituximab
Drug · Biological
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
23
States / cities
Huntsville, Alabama • Gilbert, Arizona • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced May 21, 2026, 11:25 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Peripheral T-Cell Lymphoma
Interventions
Pembrolizumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
6
States / cities
Duarte, California • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced May 21, 2026, 11:25 PM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Lymphoma
Interventions
Zolinza (vorinostat), Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 8, 2014 · Synced May 21, 2026, 11:25 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Relapsed or Refractory Peripheral T-Cell Lymphoma
Interventions
Tipifarnib
Drug
Lead sponsor
Kura Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
5
States / cities
Palo Alto, California • New Haven, Connecticut • Tampa, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced May 21, 2026, 11:25 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Hodgkin Disease, Peripheral T Cell Lymphoma
Interventions
brentuximab vedotin, bendamustine, dacarbazine, nivolumab
Drug
Lead sponsor
Seagen Inc.
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2023
U.S. locations
49
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 43 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2024 · Synced May 21, 2026, 11:25 PM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
Lymphoma, Malignant, Non-hodgkin Lymphoma
Interventions
DS-3201b
Drug
Lead sponsor
Daiichi Sankyo Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
10
States / cities
Duarte, California • New Haven, Connecticut • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced May 21, 2026, 11:25 PM EDT
Not listed Phase 2 Interventional Results available
View directory record Official record
Conditions
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Hepatosplenic T-cell Lymphoma, Peripheral T-cell Lymphoma, Stage I Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IA Mycosis Fungoides/Sezary Syndrome, Stage IB Mycosis Fungoides/Sezary Syndrome, Stage II Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IIA Mycosis Fungoides/Sezary Syndrome, Stage IIB Mycosis Fungoides/Sezary Syndrome, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IIIA Mycosis Fungoides/Sezary Syndrome, Stage IIIB Mycosis Fungoides/Sezary Syndrome, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IVA Mycosis Fungoides/Sezary Syndrome, Stage IVB Mycosis Fungoides/Sezary Syndrome
Interventions
romidepsin, lenalidomide, laboratory biomarker analysis
Drug · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
5
States / cities
Duarte, California • New Haven, Connecticut • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2024 · Synced May 21, 2026, 11:25 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Cutaneous T-cell Lymphoma, T-Prolymphocytic Leukemia, T-Large Granulocytic Leukemia, T-Lymphoblastic Leukemia/Lymphoma, Peripheral T-Cell Lymphoma
Interventions
Romidepsin, Busulfan, Fludarabine, Stem Cell Transplant, Thymoglobulin
Drug · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced May 21, 2026, 11:25 PM EDT
Withdrawn Phase 2 Interventional
View directory record Official record
Conditions
Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma, Recurrent Follicular T-Cell Lymphoma, Recurrent Hepatosplenic T-Cell Lymphoma, Recurrent Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified, Recurrent Subcutaneous Panniculitis-Like T-Cell Lymphoma, Refractory Angioimmunoblastic T-Cell Lymphoma, Refractory Enteropathy-Associated T-Cell Lymphoma, Refractory Follicular T-Cell Lymphoma, Refractory Hepatosplenic T-Cell Lymphoma, Refractory Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory Subcutaneous Panniculitis-Like T-Cell Lymphoma
Interventions
Brentuximab Vedotin, Pembrolizumab
Drug · Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 9, 2023 · Synced May 21, 2026, 11:25 PM EDT
Terminated Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Lymphoma, Follicular, Cancer, Neoplasm, Tumor, Lymphoma, Malignant, Lymphoma, B-cell, Lymphoma, Non-Hodgkin, B-Cell Chronic Lymphocytic Leukemia, B-Cell Leukemia, Chronic, B-Lymphocytic Leukemia, Chronic, Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Chronic, Leukemia, Lymphocytic, Chronic, B Cell, Myelofibrosis, Chronic Idiopathic Myelofibrosis, Idiopathic Myelofibrosis, Lymphoma, T Cell, Peripheral, Peripheral T-Cell Lymphoma, T-Cell Lymphoma, Peripheral
Interventions
ASN002 Dose Escalation, ASN002 RD
Drug
Lead sponsor
Asana BioSciences
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
12
States / cities
Tempe, Arizona • San Francisco, California • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2023 · Synced May 21, 2026, 11:25 PM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
LGLL - Large Granular Lymphocytic Leukemia, Primary Cutaneous Gamma-Delta T-Cell Lymphoma, Primary Cutaneous CD8+ Aggressive Epidermotropic T-Cell Lymphoma, Hepatosplenic T-cell Lymphoma, Subcutaneous Panniculitis-Like T-Cell Lymphoma, Aggressive NK Cell Leukemia, Systemic EBV1 T-cell Lymphoma, if CD8 Positive, Hydroa Vacciniforme-Like Lymphoproliferative Disorder, Extranodal NK/T Cell Lymphoma, Nasal Type, Enteropathy-Associated T-Cell Lymphoma, Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma, Cytotoxic PTCL-NOS (CD8+ or CD56+ and Cytotoxic Marker), Cutaneous PTCL-NOS (CD8+ or CD56+ and Cytotoxic Marker)
Interventions
DR-01
Drug
Lead sponsor
Dren Bio
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
15
States / cities
Birmingham, Alabama • Duarte, California • Irvine, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced May 21, 2026, 11:25 PM EDT